X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (48) 48
high energy physics - experiment (40) 40
[ phys.hexp ] physics [physics]/high energy physics - experiment [hep-ex] (39) 39
experiment (39) 39
particle physics (39) 39
physics (39) 39
physics - high energy physics - experiment (37) 37
female (28) 28
male (28) 28
aged (22) 22
middle aged (18) 18
research (16) 16
anaplastic lymphoma kinase (14) 14
medical and health sciences (14) 14
medicin och hälsovetenskap (14) 14
neuroblastoma (14) 14
risk factors (14) 14
high energy physics (13) 13
cancer (12) 12
clinical medicine (12) 12
klinisk medicin (12) 12
animals (11) 11
diabetes (11) 11
genetic aspects (11) 11
genetics (11) 11
nuclear experiment (11) 11
abridged index medicus (10) 10
adult (10) 10
aged, 80 and over (9) 9
genome-wide association study (9) 9
mutation (9) 9
risk (9) 9
signal transduction (9) 9
studies (9) 9
type 2 diabetes (9) 9
cell and molecular biology (8) 8
cell biology (8) 8
cell- och molekylärbiologi (8) 8
endocrinology and diabetes (8) 8
endokrinologi och diabetes (8) 8
genetics & heredity (8) 8
genomes (8) 8
hemic and lymphatic diseases (8) 8
kinases (8) 8
medicine, general & internal (8) 8
oncology (8) 8
polymorphism, single nucleotide (8) 8
population (8) 8
receptor tyrosine kinase (8) 8
surgery (8) 8
activating mutations (7) 7
age factors (7) 7
biochemistry & molecular biology (7) 7
body mass index (7) 7
care and treatment (7) 7
gene (7) 7
health aspects (7) 7
lymphomas (7) 7
mice (7) 7
multidisciplinary sciences (7) 7
prognosis (7) 7
receptor protein-tyrosine kinases - genetics (7) 7
biology (6) 6
cancer and oncology (6) 6
cancer och onkologi (6) 6
crizotinib (6) 6
diabetes mellitus, type 2 - genetics (6) 6
expression (6) 6
genetic predisposition to disease (6) 6
incidence (6) 6
insulin (6) 6
loci (6) 6
lung-cancer (6) 6
lymphoma (6) 6
medicine (6) 6
metaanalysis (6) 6
neuroblastoma - genetics (6) 6
obesity (6) 6
patients (6) 6
survival (6) 6
analysis (5) 5
basic medicine (5) 5
clinical trials (5) 5
dementia (5) 5
diabetes mellitus (5) 5
endocrine system diseases (5) 5
ethnicity (5) 5
gene expression (5) 5
genetic research (5) 5
glycemic traits (5) 5
insulin resistance (5) 5
large-cell lymphoma (5) 5
ligands (5) 5
lung cancer (5) 5
medical genetics (5) 5
medicinsk genetik (5) 5
mortality (5) 5
mutations (5) 5
phosphorylation (5) 5
polymorphism, single nucleotide - genetics (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


SAE technical paper series, Volume 811274.
In the articulated Scania bus built on the standard BR112 chassis, the engine is transversely mounted at the extreme rear. The bus is of the “pusher” type and... 
Chassis | Buses
eJournal
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 389, Issue 10073, pp. 1011 - 1024
Summary Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | THERAPY | ADENOCARCINOMA | CHEMORADIOTHERAPY | FOLINIC ACID | MODEL | CHEMOTHERAPY | Capecitabine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Carcinoma, Pancreatic Ductal - surgery | Antimetabolites, Antineoplastic - administration & dosage | Pancreatic Neoplasms - drug therapy | Aged, 80 and over | Adult | Carcinoma, Pancreatic Ductal - mortality | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Chemotherapy, Adjuvant | Deoxycytidine - administration & dosage | Pancreatic Neoplasms - surgery | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Pancreatic Ductal - drug therapy | Capecitabine - adverse effects | Antimetabolites, Antineoplastic - adverse effects | Aged | Deoxycytidine - analogs & derivatives | Antimitotic agents | Cancer patients | Care and treatment | Pancreatic cancer | Clinical trials | Product development | Metastasis | Comparative analysis | Antineoplastic agents | Studies | Antigens | Chemotherapy | Acids | Pragmatism | Pharmaceutical industry | Cancer therapies | Abdomen | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Surgery | Kirurgi
Journal Article
PloS one, ISSN 1932-6203, 01/2014, Volume 9, Issue 1, p. e86792
Journal Article
Nature reviews. Cancer, ISSN 1474-1768, 2013, Volume 13, Issue 10, pp. 685 - 700
The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many cancer types, from very rare cancers to the more prevalent non-small-cell... 
ANAPLASTIC LYMPHOMA KINASE | MOLECULAR CHARACTERIZATION | LUNG-CANCER | NPM-ALK | ONCOLOGY | INFLAMMATORY MYOFIBROBLASTIC TUMOR | DOWN-REGULATION | TRUNCATED FORM | FUSION GENE | LARGE-CELL LYMPHOMA | GROWTH-FACTOR | Translocation, Genetic | Pyrazoles - therapeutic use | Humans | Neoplasm Proteins - physiology | Receptor Protein-Tyrosine Kinases - biosynthesis | Receptor Protein-Tyrosine Kinases - physiology | Gene Expression Regulation, Neoplastic | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Lymphoma, Large-Cell, Anaplastic - enzymology | Oncogene Proteins, Fusion - physiology | Protein-Tyrosine Kinases - physiology | Drosophila Proteins - physiology | Neoplasms - genetics | Cell Transformation, Neoplastic - genetics | Gene Expression Regulation, Developmental | Neoplasm Proteins - genetics | Lymphoma, Large-Cell, Anaplastic - genetics | Pyridines - therapeutic use | Signal Transduction | Neoplasm Proteins - biosynthesis | Enzyme Induction | Models, Molecular | Neoplasms - enzymology | Neoplasm Proteins - chemistry | Clinical Trials as Topic | Zebrafish Proteins - physiology | Neoplasms - drug therapy | Animals | Receptor Protein-Tyrosine Kinases - genetics | Models, Biological | Oncogene Proteins, Fusion - genetics | Protein Conformation | Caenorhabditis elegans Proteins - physiology | Mice | Mutation | Receptor Protein-Tyrosine Kinases - chemistry | Crizotinib | Care and treatment | Lymphomas | Dosage and administration | Research | Cancer
Journal Article
Clinical epigenetics, ISSN 1868-7083, 2019, Volume 11, Issue 1, pp. 28 - 12
Journal Article
Biochemical journal, ISSN 1470-8728, 2009, Volume 420, Issue 3, pp. 345 - 361
RTKs (receptor tyrosine kinases) play important roles in cellular proliferation and differentiation. In addition, RTKs reveal oncogenic potential when their... 
Extracellular-signal-regulated kinase (ERK) | Pleiotrophin | Anaplastic large cell lymphoma (ALCL) | Neuroblastoma | Non-small cell lung cancer (NSLCL) | Midkine | Anaplastic lymphoma kinase (ALK) | Inflammatory myofibroblastic tumour (IMT) | ALK PROTEIN EXPRESSION | inflammatory myofibroblastic tumour (IMT) | NPM-ALK | HEPARIN-BINDING | GROWTH-FACTOR PLEIOTROPHIN | non-small cell lung cancer (NSLCL) | BIOCHEMISTRY & MOLECULAR BIOLOGY | anaplastic lymphoma kinase (ALK) | EML4-ALK FUSION GENE | neuroblastoma | LARGE-CELL LYMPHOMA | extracellular-signal-regulated kinase (ERK) | pleiotrophin | NEUROTROPHIC FACTOR HBNF | INFLAMMATORY MYOFIBROBLASTIC TUMOR | NON-HODGKINS-LYMPHOMA | midkine | anaplastic large cell lymphoma (ALCL) | RECEPTOR TYROSINE KINASE | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Oncogene Proteins, Fusion - metabolism | Signal Transduction | Carcinoma, Non-Small-Cell Lung - genetics | Protein-Tyrosine Kinases - metabolism | Humans | Lung Neoplasms - metabolism | Neuroblastoma - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Lung Neoplasms - pathology | Nuclear Proteins - metabolism | Receptor Protein-Tyrosine Kinases | Protein-Tyrosine Kinases - genetics | Models, Biological | Oncogene Proteins, Fusion - genetics | Lymphoma, Large-Cell, Anaplastic - pathology | Neuroblastoma - metabolism | Nuclear Proteins - genetics | Lymphoma, Large-Cell, Anaplastic - metabolism | Neuroblastoma - pathology | Lymphoma, Large-Cell, Anaplastic - genetics | ALK, anaplastic lymphoma kinase | LTK, leucocyte tyrosine kinase | MUC-1, mucin-1 | IRS-1, IR substrate-1 | PTN, pleiotrophin | TGFβ, transforming growth factor β | ERK, extracellular-signal-regulated kinase | PKB, protein kinase B | Shc, Src homology and collagen homology | TPM, tropomyosin | IMP cyclohydrolase | MK, midkine | MYH9, non-muscle myosin heavy chain | MAM, meprin, A5 protein and receptor protein tyrosine phosphatase mu | NPM, nucleophosmin | mTOR, mammalian target of rapamycin | NIPA, nuclear interacting partner of ALK | RPTP, receptor protein tyrosine phosphatase | DLBCL, diffuse large B-cell lymphoma | FOXO3a, forkhead box O 3a | NF-κB, nuclear factor κB | Shp1, SH2 domain-containing phosphatase 1 | RANBP2, Ran-binding protein 2 | ALCL, anaplastic large cell lymphoma | Dpp, decapentaplegic | FRS2, fibroblast growth factor receptor substrate 2 | LDLa, low-density lipoprotein class A | EGFR, epidermal growth factor receptor | SEC31L1, SEC31 homologue A | GIST, gastrointestinal stromal tumour | RTK, receptor tyrosine kinase | SH2, Src homology 2 | TFG, TRK-fused gene | ATIC, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase | CLTC, clathrin heavy chain | MAPK, mitogen-activated protein kinase | Hen-1, hesitation-1 | MEK, MAPK | PI3K, phosphoinositide 3-kinase | HEK, human embryonic kidney | SCD-2, suppressor of constitutive dauer 2 | Review | EBPβ, CCAAT | CARS, cysteinyl-tRNA synthetase | JNK, c-Jun N-terminal kinase | ERK kinase | Grb2, growthfactor-receptor-bound protein 2 | SCC, squamous cell carcinoma | EML4, echinoderm microtubule-associated protein like 4 | SHH, sonic hedghog | BCR-Abl, breakpoint cluster region-Abl | IR, insulin receptor | ALO17, ALK lymphoma oligomerization partner on chromosome 17 | enhancer-binding protein β | PLCγ, phospholipase Cγ | NSCLC, non-small cell lung cancer | UCN-01, unco-ordinated 1 | Cdc42, cell division cycle 42 | STAT, signal transducer and activator of transcription | DRG, dorsal root ganglia | MSN, moesin | dALK, Drosophila ALK | IL-3, interleukin-3 | CNS, central nervous system | JAK, Janus kinase | CML, chronic myeloid leukaemia | Jeb, jelly belly | IMT, inflammatory myofibroblastic tumour
Journal Article
Science signaling, ISSN 1945-0877, 11/2017, Volume 10, Issue 507, p. eaam7550
Activation of the RAS-RAF-MEK-ERK signaling pathway is implicated in driving the initiation and progression of multiple cancers. Several inhibitors targeting... 
RAS | BIOCHEMISTRY & MOLECULAR BIOLOGY | ALK MUTATIONS | AKT | LARGE-CELL LYMPHOMA | HIGH-RISK NEUROBLASTOMA | COMPLEX INTEGRITY | NEGATIVE FEEDBACK | MUTANT LUNG-CANCER | UP-REGULATION | ACTIVATING MUTATIONS | CELL BIOLOGY | Lung Neoplasms - drug therapy | Oncogene Proteins, Fusion - metabolism | Humans | Neuroblastoma - enzymology | Antineoplastic Agents - therapeutic use | Mitogen-Activated Protein Kinase 7 - antagonists & inhibitors | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Pyrimidinones - pharmacology | Antineoplastic Agents - pharmacology | Mechanistic Target of Rapamycin Complex 2 - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - metabolism | Lung Neoplasms - enzymology | Pyrimidinones - therapeutic use | Mitogen-Activated Protein Kinase 7 - metabolism | Xenograft Model Antitumor Assays | Mechanistic Target of Rapamycin Complex 2 - metabolism | Animals | MAP Kinase Signaling System - drug effects | Receptor Protein-Tyrosine Kinases - genetics | Protein Kinase Inhibitors - therapeutic use | Neuroblastoma - drug therapy | Cell Line, Tumor | Oncogene Proteins, Fusion - antagonists & inhibitors | Mice | Mice, Inbred BALB C | Protein Kinase Inhibitors - pharmacology | Pyridones - therapeutic use | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Pyridones - pharmacology | TOR protein | Biotechnology | Phosphorylation | Xenotransplantation | Lung cancer | Raf protein | AKT protein | Activation | Neuroblastoma | Kinases | Neuroblastoma cells | Signal transduction | Feedback | Xenografts | Inhibition | Protein-tyrosine kinase | Epidermal growth factor receptors | Therapeutic applications | MEK inhibitors | Extracellular signal-regulated kinase | Non-small cell lung carcinoma | MAP kinase | Rapamycin | Patients | Lymphoma | Signaling | Inhibitors | Mutation | Cancer | Cell and Molecular Biology | Cell- och molekylärbiologi
Journal Article
APMIS, ISSN 0903-4641, 05/2019, Volume 127, Issue 5, pp. 288 - 302
Journal Article